Patents by Inventor Daigen Xu

Daigen Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS
    Publication number: 20230322934
    Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-?v integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.
    Type: Application
    Filed: October 28, 2022
    Publication date: October 12, 2023
    Applicant: Merck Patent GmbH
    Inventors: Ilhan CELIK, Eike Staub, Miriam Urban, Sabine Raab-Westphal, Eileen Samy, Andrew Bender, Georgianna Varrone, Yin Wu, Daigen Xu
  • Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
    Patent number: 11485786
    Abstract: The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting ?v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: November 1, 2022
    Assignee: Merck Patent GmbH
    Inventors: Ilhan Celik, Eike Staub, Miriam Urban, Sabine Raab, Eileen Samy, Andrew Bender, Georgianna Higginbotham, Yin Wu, Daigen Xu
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS
    Publication number: 20200002424
    Abstract: The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting ?v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.
    Type: Application
    Filed: August 15, 2019
    Publication date: January 2, 2020
    Applicant: Merck Patent GmbH
    Inventors: Ilhan CELIK, Eike Staub, Miriam Urban, Sabine Raab, Eileen Samy, Andrew Bender, Georgianna Higginbotham, Yin Wu, Daigen Xu
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS
    Publication number: 20190144547
    Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-?v integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 16, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Ilhan CELIK, Eike STAUB, Miriam URBAN, Sabine RAAB, Eileen SAMY, Andrew BENDER, Georgianna HIGGINBOTHAM, Yin WU, Daigen XU
  • Interleukin-10 fusion proteins and uses thereof
    Patent number: 10040843
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 7, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • Assays for BTK inhibitors
    Patent number: 10012650
    Abstract: The present invention relates to BTK occupancy assays.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: July 3, 2018
    Assignee: Merck Patent GmbH
    Inventors: Andrew Bender, Lesley Liu-Bujalski, Albertina Pereira, Richard D. Caldwell, Roland Grenningloh, Daigen Xu
  • INTERLEUKIN-10 FUSION PROTEINS AND USES THEREOF
    Publication number: 20160340413
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: April 27, 2016
    Publication date: November 24, 2016
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • ASSAYS FOR BTK INHIBITORS
    Publication number: 20160169894
    Abstract: The present invention relates to BTK occupancy assays.
    Type: Application
    Filed: December 10, 2015
    Publication date: June 16, 2016
    Inventors: Andrew BENDER, Lesley LIU-BUJALSKI, Albertina PEREIRA, Richard D. CALDWELL, Roland GRENNINGLOH, Daigen XU
  • Interleukin-10 fusion proteins
    Patent number: 9346872
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: May 24, 2016
    Assignee: ROCHE GLYCART AG
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • INTERLEUKIN-10 FUSION PROTEINS AND USES THEREOF
    Publication number: 20150218244
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). More particularly, the invention concerns fusion proteins of antibodies and mutant IL-10 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Thomas Emrich, Pablo Umana, Ekkehard Moessner, Ralf Hosse, Jens Fischer, Lydia Jasmin Hanisch, Daigen Xu
  • INTERLEUKIN-10 FUSION PROTEINS AND USES THEREOF
    Publication number: 20140044674
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 13, 2014
    Applicant: Roche Glycart AG
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • Methods for Treating or Preventing Neoplasias
    Publication number: 20090192158
    Abstract: The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.
    Type: Application
    Filed: April 30, 2007
    Publication date: July 30, 2009
    Inventors: Stacia Kargman, Gary O'Neill, Daigen Xu
  • Methods for enhancing survival of a neuron
    Patent number: 6709866
    Abstract: NAIP and IAP polypeptides prevent neuronal cell death caused by ischemia, neurodegenerative conditions, and axotomy. The invention provides methods for neuroprotection by the prevention of cell death and kits and methods for the identification of neuroprotective therapeutic compounds.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: March 23, 2004
    Assignee: Aegera Therapeutics, Inc.
    Inventors: George S. Robertson, Robert G. Korneluk, Alexander E. MacKenzie, Daigen Xu, Stephen J. Crocker
  • Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
    Publication number: 20010021699
    Abstract: NAIP and IAP polypeptides prevent neuronal cell death caused by ischemia, neurodegenerative conditions, and axotomy. The invention provides methods for neuroprotection by the prevention of cell death and kits and methods for the identification of neuroprotective therapeutic compounds.
    Type: Application
    Filed: February 20, 2001
    Publication date: September 13, 2001
    Applicant: University of Ottawa
    Inventors: George S. Robertson, Robert G. Korneluk, Alexander E. MacKenzie, Daigen Xu, Stephen J. Crocker
  • Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
    Patent number: 6159948
    Abstract: NAIP and IAP polypeptides prevent neuronal cell death caused by ischemia, neurodegenerative conditions, and axotomy. The invention provides methods for neuroprotection by the prevention of cell death and kits and methods for the identification of neuroprotective therapeutic compounds.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: December 12, 2000
    Assignee: University of Ottawa
    Inventors: George S. Robertson, Robert G. Korneluk, Alexander E. MacKenzie, Daigen Xu, Stephen J. Crocker